Portal Innovations CEO John Flavin provides a look into the 2026 biotech M&A pipeline and breaks down Eli Lilly’s purported acquisition of CrossBridge Bio for up to $300 million, bolstering its oncology segment. He talks with Katie Greifeld and Romaine Bostick on “The Close.” (Source: Bloomberg)
www.bloomberg.com
#Portal #CEO #Lilly #Deal #Cancer #Biotech #CrossBridge
Portal CEO on Lilly Deal for Cancer Biotech CrossBridge
